Northwestern Mutual Wealth Management Co. Raises Stake in Fulgent Genetics, Inc. $FLGT

Northwestern Mutual Wealth Management Co. lifted its position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) by 2,984,354.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,522,072 shares of the company’s stock after purchasing an additional 1,522,021 shares during the quarter. Northwestern Mutual Wealth Management Co. owned about 4.92% of Fulgent Genetics worth $39,985,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Farther Finance Advisors LLC grew its holdings in shares of Fulgent Genetics by 69.3% during the 4th quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock worth $35,000 after purchasing an additional 548 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Fulgent Genetics during the 2nd quarter worth about $49,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Fulgent Genetics during the 4th quarter worth about $56,000. Quantbot Technologies LP purchased a new stake in shares of Fulgent Genetics during the 3rd quarter worth about $61,000. Finally, Unison Advisors LLC purchased a new position in Fulgent Genetics in the 4th quarter worth approximately $230,000. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Piper Sandler restated a “neutral” rating and issued a $15.00 price target (down from $30.00) on shares of Fulgent Genetics in a report on Tuesday, May 5th. Zacks Research cut Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Wall Street Zen cut Fulgent Genetics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fulgent Genetics in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $27.00.

Fulgent Genetics Stock Up 1.0%

NASDAQ FLGT opened at $15.85 on Tuesday. The stock has a market cap of $471.54 million, a PE ratio of -6.63 and a beta of 0.88. Fulgent Genetics, Inc. has a fifty-two week low of $13.46 and a fifty-two week high of $31.04. The business has a 50 day moving average price of $15.65 and a two-hundred day moving average price of $22.27.

Fulgent Genetics (NASDAQ:FLGT) last released its quarterly earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.14. The firm had revenue of $83.34 million during the quarter, compared to analysts’ expectations of $85.38 million. Fulgent Genetics had a negative return on equity of 3.24% and a negative net margin of 23.04%.Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. Sell-side analysts anticipate that Fulgent Genetics, Inc. will post -2.81 EPS for the current fiscal year.

Fulgent Genetics Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.